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Abstract Methods to precisely control growth factor presen-
tation in a local and sustained fashion are of increasing interest
for a number of complex tissue engineering applications. The
cytokine transforming growth factor beta (TGFβ) plays a key
role in promoting the chondrogenic differentiation of human
mesenchymal stem cells (hMSCs). Traditional chondrogenic
approaches utilize soluble delivery, an approach with limited
application for clinical translation. In this work, we introduce
a reactive thiol onto TGFβ and covalently tether the growth
factor into poly(ethylene glycol) (PEG) hydrogels using a
photoinitiated thiol-acrylate polymerization mechanism. We
demonstrate the bioactivity of thiolated TGFβ, before and
after polymerization, using a SMAD2 reporter cell line.
hMSCs were encapsulated in PEG hydrogels with and without
tethered TGFβ, and subsequently assayed for glycosamino-
glycan and collagen II production as indicators of chondro-
genesis. Over a 21-day time course, tethered TGFβ promoted
chondrogenesis at levels similar to a positive control using
solubly dosed growth factor. These results provide evidence
that tethered TGFβ materials can be successfully used to
promote chondrogenic differentiation of MSCs.
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Introduction
There is growing interest in methods to sequester and present
bioactive therapeutic proteins to cells immobilized in 3D ma-
trices, specifically for application in the areas of stem cell
culture and regenerative medicine [1]. Numerous biological
processes are regulated throughprotein signaling.For example,
cytokines and chemokines are a particularly attractive target for
tissue engineering applications, since these biomolecules are
directly involved in controlling critical cell functions like pro-
liferation, differentiation, and chemotaxis. Typically, these pro-
teins are potent at concentrations as low as nano- to picomolar
[2–4], andmany of them function via interactionwith extracel-
lular surface receptors [5], which then regulate changes in gene
expression. Growth factors are commonly dosed solubly via
culture media in vitro; however, in vivo, these proteins are
sequestered in the extracellular matrix, and these sequestered
factors are then available to nearby cells.
Hydrogel scaffolds are increasingly utilized to reconstruct
and study such complex 3D interactions. The cellular micro-
environment plays a key role in providing diverse cues that
direct cell function in vivo [6, 7]. The extracellular matrix
itself provides not only a niche for cell attachment, but also
acts as a storage depot for signaling proteins [2, 6, 7], and
there is growing interest in strategies that recapitulate aspects
of these functionalities using synthetic hydrogel scaffolds.
Sequestered protein approaches also address practical impli-
cations for growth factor delivery. Growth factors are typically
cross-reactive with multiple cell types and are reported to have
short serum half-lives [3], limitations that often necessitate
localized presentation, rather than systemic dosing. Addition-
ally, immobilizing such proteins allows control of total dose
delivered and can increase the safety and persistence of sig-
naling. Indeed, immobilizing growth factors in a bioactive,
physiologically relevant context is an important step towards
clinical implementation for regenerative medicine as a whole.
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Recently, a number of growth factors have been immobilized
into synthetic substrates, including VEGF [8], PDGF [9], and
transforming growth factor beta (TGFβ) [10–13] and shown
to maintain bioactivity while tethered. Covalent incorporation
of such potent cell-directing proteins into hydrogels suggests
an attractive approach to design cell delivery scaffolds for
locally directing and guiding cell properties important for
tissue regeneration.
In this regard, we were particularly interested in modify-
ing poly(ethylene glycol) (PEG) hydrogels with proteins, as
these systems are broadly explored for cell delivery appli-
cations [14–18] and the low fouling properties of PEG
render it useful for examining the effects of particular pro-
tein signals on encapsulated cell function. One widely used
approach for forming PEG hydrogels is through the photo-
initiated chain polymerization of di(meth)acrylated PEG
monomers. Photopolymerization allows for precise spatial
and temporal control of polymerization and can be carried
out at physiological temperature in aqueous conditions. The
resulting crosslinked PEG hydrogels have enjoyed wide
utilization for encapsulation of numerous cells types with
high cell survival reported following photoencapsulation
[19–21]. However, less explored is the mixed-mode thiol-
acrylate photopolymerization [15] that provides a facile
method for incorporating thiol-functionalized molecules
during polymerization of acrylate functional groups [22].
Our group has successfully used this approach to incorpo-
rate a number of peptide functionalities into PEG hydrogels,
including adhesive motifs [22, 23], affinity-binding ligands
[24, 25], and enzyme-cleavable peptides [22, 26]; however,
proteins have been less explored. We hypothesized that a
thiolated growth factor, such as TGFβ, could be incorporat-
ed into PEG hydrogels via a thiol-acrylate photopolymeri-
zation while maintaining its activity and accessibility for
cell binding. Specifically, we were interested in exploring
how this method might be useful for locally promoting the
chondrogenesis of human mesenchymal stem cells (hMSCs)
in the absence of exogenously delivered TGFβ.
In this work, TGFβ was thiolated and covalently incor-
porated into PEG diacrylate hydrogels using a photoinitiated
thiol-acrylate polymerization scheme (Scheme 1). We con-
firmed that thiolated TGFβ had bioactivity similar to that of
the native, unmodified growth factor, using a cell reporter
assay for SMAD2 signaling. By varying the concentration
of thiolated TGFβ in the monomer solution, the total growth
factor concentration in the final gel was readily controlled,
as determined by a modified surface ELISA. Bioactivity of
the tethered growth factor and the ability for it to signal
encapsulated cells was further confirmed using the SMAD2
reporter cell line. Finally, we demonstrate the potential of
this material platform by encapsulating hMSCs in order to
promote chondrogenic differentiation. mesenchymal stem
cells (MSCs) in tethered TGFβ hydrogels produced
extracellular matrix proteins (ECM) proteins indicative of
chondrogenic differentiation. Namely, MSC cultured in gels
with tethered TGFβ produced glycosaminoglycan (GAG)
and collagen II at levels similar to or exceeding that of
positive controls, where TGFβ was dosed solubly in the
culture media. We believe these results indicate the clinical
potential of tethered growth factor biomaterial platforms as a
cell delivery system for tissue engineering applications de-
manding tunable control of bioactive protein signals in a
local and sustained manner.
Materials and methods
Cell culture and expansion
hMSCs were isolated from bone marrow aspirate (Lonza
Biosciences) as detailed elsewhere [27]. Cells were cultured
in growth medium consisting of low-glucose DMEM sup-
plemented with 10 % fetal bovine serum, 1 μg/mL ampho-
tericin B, 50 U/mL penicillin, 50 μg/mL streptomycin, and
20 μg/mL gentamicin. Cultures were maintained at 5 % CO2
and 37 °C, and hMSCs were passaged up to three times
prior to encapsulation studies.
PE25 cells were cultured in growth medium identical to
that used for hMSCs. For analysis of TGFβ bioactivity,
plated cells were cultured in serum-free DMEM supple-
mented with 1 μg/mL amphotericin B, 50 U/mL penicillin,
50 μg/mL streptomycin, and 20 μg/mL gentamicin, aug-
mented with either native (non-thiolated) or thiolated TGFβ
at 5 ng/mL.
Scheme 1 Photoinitiated thiol-acrylate polymerization scheme
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Monomer synthesis
Poly(ethylene glycol) (Mn04,600) diacrylate (PEGDA) was
synthesized as previously described [25]. Briefly, poly(eth-
ylene glycol) (PEG) was dissolved in toluene and reacted
with acryoyl chloride in the presence of triethylamine over-
night under argon. The product was filtered through alumina
oxide and neutralized with sodium carbonate. The filtrate
was then precipitated in cold ethyl ether. Proton NMR was
used to verify yield; typical functionalization for the PEG
material used in this study was greater than 95 %.
Growth factor incorporation into PEG hydrogels
2-Iminothiolane (Pierce) was purchased and used to thiolate
TGFβ (isoform 1) (Peprotech) according to the manufac-
turer's recommendations. Following the reaction, thiolated-
TGFβ was aliquoted until used. Thiolated-TGFβ was then
reacted into PEG hydrogels via thiol-acrylate polymeriza-
tion with the PEGDA monomer at concentrations of 0, 1,
10, or 100 nM. The hydrogels with the tethered growth
factor were incubated overnight in phosphate-buffered sa-
line (PBS), and the TGFβ surface density was measured
using a modified ELISA as described elsewhere [12].
Briefly, gels were incubated overnight in a blocking
solution of 1 % bovine serum albumin (BSA) in PBS con-
taining 0.05 % Tween-20 (PBS-T). Gels were washed 3× in
PBS-T prior to incubation with a biotinylated anti-TGFβ
antibody (eBioscience) for 1 h at room temperature. Gels
were washed 3x in PBS-T, and incubated with avidin-HRP
(eBioscience) for 30 min, and washed 3× in PBS-T. After
washing overnight in PBS-T, gels were incubated with
3,3′,5,5′ tetramethylbenzidine substrate until color devel-
oped, at which time the reaction was stopped using 2 N
sulfuric acid. The solutions were then measured for optical
density at 450 nm using a Bioteck H1 spectrophotometer.
Bioactivity of thiolated TGFβ
PE25 cells were plated in 12-well plates at a density of
200,000 cells/well, then incubated with serum-free DMEM
media augmented with 1 ng/mL native (non-thiolated)
TGFβ (Peprotech) or thiolated TGFβ. Cells were incubated
overnight at 37 °C, then analyzed using Glo–Lysis compo-
nents from Promega.
Alternatively, PE25 cells were encapsulated in PEG gels
using a formulation of 10 wt% PEGDA, 1 mM lithium acyl
phosphinate (LAP) initiator, 1 mM Cys–Arg–Gly–Asp–Ser
(CRGDS) peptide, and 0, 12.5 nM, 25 nM, or 50 nM
thiolated-TGFβ. PE25 cells were suspended at densities of
1, 5, 10, and 25 million cells/mL of solution, and cell-laden
hydrogels were formed at a volume of 40 μL (O.D. ~5 mm,
thickness~2 mm) using photoinitiation (Io ~3.5 mW/cm
2 at
λ0365 nm) for 180 s. Immediately following encapsulation,
hydrogels were placed into growth medium in 48-well
plates and incubated overnight at 37 °C, 5 % CO2. Follow-
ing incubation, hydrogels were placed in Glo–Lysis buffer
(Promega) for not less than 10 min and frozen at −70 °C for
greater than 2 h. Lysate was incubated with luciferase sub-
strate (Promega) and luminescence was monitored on a
Biotek H1 Hybrid spectrophotometer.
hMSC encapsulation in PEGDA hydrogels
hMSCs were encapsulated at 10×106 cells/mL in 10-wt%
PEGDA (Mn04,600) solution, with 2 mM CRGDS adhesive
peptide and 1 mM LAP photoiniator. Thiolated TGFβ con-
centrations of 0, 1, 10, or 100 nM were used to form tethered
hydrogels. Polymerization was initiated with light (Io0
~3.5 mW/cm2, λ0365 nm) under sterile conditions to create
40 μL gels (O.D. ~5 mm, thickness ~2 mm), and cell-laden
gels were immediately placed into experimental culture
medium. Growth medium (described previously) was used
for a negative control, and chondrogenic medium (high-
glucose DMEM, 1 μg/mL amphotericin B, 50 U/mL peni-
cillin, 50 μg/mL streptomycin, 20 μg/mL gentamicin,
100 nM dexamethasone, ITS+premix (6.25 μg/mL bovine
insulin, 6.25 μg/mL transferrin, 6.25 μg/mL selenous acid,
5.33 μg/mL linoleic acid, and 1.25 μg/mL bovine serum
albumin), 100 μg/mL sodium pyruvate, and 50 μg/mL
ascorbic acid 2-phosphate) with 5 ng/mL soluble TGFβ
was used as a positive control for chondrogenesis. Hydro-
gels with tethered TGFβ (1, 10, or 100 nM) were cultured in
chondrogenic medium, but in the absence of soluble TGFβ
added to the media. Samples were harvested at days 0, 7, 14,
and 21 for analysis of chondrogenesis.
DNA quantification of encapsulated hMSCs
Immediately following photoencapsulation, cell-laden
hydrogels (n03) were placed into an enzymatic digest buffer
(125 μg/mL papain (Worthington Biochemical), 10 mM
cysteine) overnight at 60 °C, then frozen prior to analysis.
Samples were similarly harvested at days 7 and 14, and
these solutions were then assayed for DNA content using a
Picogreen assay (Invitrogen) to quantify changes in cell
number between various culture conditions.
Glycosaminoglycan production assay
Dimethyl methylene blue (DMMB) assay was used to quan-
tify GAG production in hydrogel scaffolds. Cell-laden gels
were harvested at pre-determined timepoints (days 0, 7, and
14) and incubated overnight at 60 °C in 125 μg/mL papain,
10 mM cysteine. Samples were then incubated with DMMB
dye and analyzed for chondroitin sulfate content by
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measuring absorbance at 525 nm using a Biotek H1 spec-




formalin, 30% sucrose at 4 °C for 48 h. Following fixing, gels
were frozen and cryosectioned at 30μmusing aLeicaCM1850
Cryostat. Samples were stained for Safranin-O on a Leica
Autostainer XL and imaged in bright field (×40) on a Nikon
inverted microscope. For immunostaining, sections were
blocked in 10%goat serumwith1%BSA, then incubatedwith
antibodies for collagen type II (abcam) andCD105 (Sigma) for
2 h.Alexa Fluor-conjugated secondary antibodies (Invitrogen)
and 4′,6-diamidino-2-phenylindole (DAPI) were used to fluo-
rescently label proteins of interest. Images were collected on a
Zeiss LSM710 scanning confocal microscope. Quantification
of collagen II or CD-105-positive cells was performed on ×10
images (three per sample, n03 samples) by counting the num-
ber of cells positive for either collagen II or CD-105, then
normalizing to total cell nuclei using DAPI.
Statistical analysis
All data were plotted and analyzed using Graphpad Prism
5.0 software. Error bars are plotted as the standard deviation
for three replicate conditions, unless otherwise noted. Sta-
tistical differences were calculated using a Student's t test.
Results and discussion
Activity of thiolated TGFβ in PEG hydrogels
To introduce a functional group on native TGFβ for subse-
quent conjugation to PEG, the protein was thiolated via the
reaction of 2-iminothiolane with primary amines, such as
that found on the N-terminus. During photopolymerization of
PEG hydrogels, this thiol can be covalently tethered into the
network via chain transfer from a propagating radical on a
growing polyacrylate kinetic chain, creating a pendant protein
presentation [28, 29]. For confirmation of TGFβ activity
following thiolation, a PE25 cell assay was utilized. This line
has been permanently transfected with a luciferase reporter for
SMAD2 activation, an indicator of TGFβ bioactivity [30].
PE25 cells were plated and incubated in medium containing
either native (non-thiolated) or thiolated TGFβ at identical
concentrations. Following an incubation period of 18 h, the
cells were lysed and assayed for luciferase activity, which
represents relative TGFβ bioactivity (Fig. 1a). Results indicate
that thiolation with 2-iminothiolane did not significantly de-
crease the bioavailability of TGFβ (p<0.005).
Thiolated TGFβ was then added to a PEGDA (Mn04,600)
monomer (10 wt%) solution at 0, 12.5, 25, 50, or 100 nM, and
the solutions were irradiated (Io~3.5 mW/cm
2, λ0365 nm) for
180 s. The resulting hydrogels were then assayed for detect-
able TGFβ concentration using a modified surface ELISA
[12]; results are presented in Fig. 1b. The ELISA confirms
TGFβ incorporation into the gel, and results show a linear
response for TGFβ in the 0–100-nM concentration range.
However, as this method only utilizes antibody recognition,
further confirmation of bioactivity of the tethered TGFβ in the
PEG hydrogel platform was required, using an encapsulation
study with the PE25 reporter cell line.
Tethered TGFβ bioactivity in 3D culture
After confirming the tunability of TGFβ concentration in
PEG hydrogels, we next wanted to investigate the bioactiv-
ity of TGFβ tethered in a 3D culture system using the thiol-
acrylate polymerization reaction. PEG diacrylate monomer
(10-wt%) was formulated with varying concentrations of
TGFβ: 0, 12.5, 25, and 50 nM. Concurrently, the seeding
density of PE25 cells was varied, with cells encapsulated at
1, 5, 10, or 25 million cells/mL. This design was chosen for
Fig. 1 TGFβ can be covalently incorporated into PEG hydrogels. a
Results from a PE25 cell assay show that thiolated TGFβ provides
identical bioactivity to that of native (non-thiolated) growth factor. b
Surface ELISA results show detection of tethered TGFβ in PEG hydro-
gels, up to a concentration of 100 nM. Monomer solutions containing
0, 12.5, 25, 50, or 100 nM thiolated TGFβ were photopolymerized
(Io03.5 mW/cm
2, λ0365 nm) and allowed to equilibrate in 1 % BSA.
A surface ELISA showed a linear correlation between detectable TGFβ
and its concentration in the initial monomer solution, providing a facile
method to control the total protein payload. *p<0.05, denotes values
statistically non-zero, and **p<0.05, denotes statistical differences
between concentrations. Both data sets are presented as mean±s.d.
(n05)
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a number of reasons. First, the effect of varying concentration
of tethered TGFβ on cellular response was characterized, to
provide insight into its bioactivity following the photoinitiated
thiol-acrylate reaction used to form these PEG hydrogels.
Secondly, this approach allowed us to test the bioavailability
of the scaffold-tethered protein to cell binding and ultimately
response. While this PEG scaffold is non-degradable, this
approach provides confirmation that tethered TGFβ is acces-
sible to encapsulated cells. This observation is similar to the
effects of adhesive peptides incorporated into non-degradable
gels, where embedded cell can bind with the tethered ligand in
the immediate pericellular space. Peptide signals often pro-
mote survival, but in a dose-dependent manner and often with
a threshold. Thus, the amount of bioactive TGFβ assayed
should be a function of both TGFβ concentration and cell
density. Results are presented in Fig. 2.
For each tethered TGFβ concentration, an increased lucif-
erase activity was observed over the lowest cell seeding den-
sities of 1, 5, and 10 million cells/mL. For gels formed with
12.5 nM TGFβ, there was no statistically significant increase
in luciferase activity when the cell seeding density was further
increased from 10 to 25 million cells/mL. This result suggests
that for the PEGDA hydrogels, at 10 MM cells/mL, tethered
TGFβ is the limiting factor for signaling, possibly due to an
excess cell-receptor concentration (i.e., a maximum cell den-
sity) or through limitations in receptor access to the tethered
growth factor. Increasing the concentration of tethered TGFβ
for higher cell densities would be expected to result in in-
creased levels of luciferase activity. This hypothesis was con-
firmed for hydrogels containing 25- and 50-nM tethered
TGFβ. Luciferase activity was 7,800 AU for 25-nM hydrogels
encapsulated at 10 MM cells/mL and increased to 12,600 AU
at the higher 25-MM cells/mL seeding density. Likewise, 50-
nM hydrogels had luciferase activity of 12,100 AU at 10 MM
cells/mL, which increased to just over 21,800AU at the higher
density of 25 MM cells/mL. Interestingly, in both the 25- and
50-nM TGFβ concentrations, increasing cell density by a
factor of 2.5 resulted in a similar increase (165–180 %) in
bioactive TGFβ. These results with the PE25 cell line dem-
onstrate the feasibility of presenting tethered TGFβ as a bio-
active signal to encapsulated cells; so we next sought to devise
a study to test the ability of these materials to promote a more
biologically relevant and complex response–chondrogenic
differentiation of mesenchymal stem cells (MSCs).
DNA quantification of hMSCs encapsulated in tethered
TGFβ hydrogels
After confirming that tethered TGFβ maintained its bioac-
tivity following photopolymerization, we then wanted to
investigate whether such a platform could promote chon-
drogenic differentiation of encapsulated hMSCs. Cells were
encapsulated at a density of 10 MM cells/mL in 10-wt%
PEGDA hydrogels with 1 mM CRGDS peptide to promote
integrin binding and survival. Immediately following photo-
polymerization, gels were assayed for DNA content via a
Picogreen assay, and subsequently tested through culture for
Fig. 3 Viability of hMSCs encapsulated in tethered TGFβ hydrogels.
DNA content of cell-laden hydrogels was assayed over 14 days of
culture, and used as a general correlative measure of cell viability.
Hydrogels cultured in growth medium (used as a negative control for
chondrogenesis) maintained initial cell counts, as did those incorporat-
ing 1-nM tethered TGFβ. Chondrogenic media samples (positive con-
trol) exhibited an increase in DNA of approximately twofold, while
TGFβ tethered at 10 or 100 nM demonstrated similar increases in DNA
content, suggesting high levels of viability of the encapsulated hMSCs.
Results are presented as mean±s.e.m. (n03)
Fig. 2 Tethered TGFβ hydrogels present a bioactive signal to encap-
sulated cells. PE25 cells were encapsulated into hydrogels formed with
12.5-, 25-, or 50-nM tethered TGFβ. Cells were encapsulated at den-
sities of 1, 5, 10, or 25 million cells/mL. For all TGFβ concentrations
tested, increasing the cell density from 1 to 10 MM cells/mL produced
increased luciferase activity, a measure of the bioactive TGFβ concen-
tration detected by the cells. Hydrogels with 12.5-nM tethered TGFβ
had no statistically significant increase in luciferase activity between
10 and 25 MM cells/mL, indicating that the amount of available
tethered growth factor is limiting. At higher TGFβ concentrations (25
and 50 nM), luciferase activity increased with increasing cell number.
For a given TGFβ concentration, t test showed significant difference
between all luciferase values except those indicated with asterisk.
Results are presented as mean activity±s.d. (n05)
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14 days. Results are presented in Fig. 3. Cells cultured in
growth medium showed little increase in DNA content over
14 days, agreeing with previous work on hMSC encapsula-
tion [27]. In contrast, samples in chondrogenic medium
exhibited a twofold increase in DNA content over the same
time course. When tethered, TGFβ was added to the hydro-
gel at the lowest concentration of 1 nM, DNA content also
remained unchanged and approximated that of the profile of
gels cultured in growth medium. At the higher concentra-
tions of 10 and 100 nM TGFβ, DNA content increased and
was along the same order of magnitude as chondrogenic
culture samples. These finding suggested that in all cases,
cell survival following photoencapsulation was robust, a
finding confirmed via histological and immunostaining
analyses in following sections.
GAG secretion of encapsulated hMSCs
GAG production is one key earlier indicator of a chondrocyte-
like phenotype [31–33]. Native cartilage is comprised primary
of sulfated GAG chains and type II collagen. A DMMB assay
was used to quantify secreted GAGs immobilized in the PEG
hydrogel scaffold, as previously described [22, 23, 34]. Results
are presented in Fig. 4a, with GAG secretion normalized to
DNA (micrograms of chondroitin sulfate A (ChSA) per nano-
gramofDNA).Forhydrogelscultured ingrowthmedium, there
was little tonomeasurableamountofGAGs.Day-0content (for
all samples) was 14.8±5.6 μg/ng, and day-14 growth samples
contained 13.2±1.8 μg/ng. As a positive control, MSC-laden
hydrogels cultured in chondrogenic medium had a marked
increase in GAG production; at day 14, chondrogenic samples
contained 70.2±5.6 μg/ng. Interestingly, tethered TGFβ at
1 nM provided a minimal increase over growth media, as cell-
laden hydrogels were assayed to contain 22.4±0.4 μg/ng at
day 14. However, at the same time point, both 10 nM (54.9±
1.1 μg/ng) and 100 nM (53.4±10.7 μg/ng) had GAG produc-
tion similar to that of the positive control, where TGFβ was
delivered solubly. At day 14, each tetheredTGFβ gel condition
resulted ina statistically significant amountofGAGproduction
relative to that of the negative control (p<0.01). Noteworthy,
however, is the total amount of growth factor delivered to
encapsulated cells in this study. In chondrogenic medium,
TGFβ is added to the media at a concentration of 5 ng/mL
(0.2 nM), which is a much lower concentration than used in
the hydrogels (1 to 100 nM). However, over 22 days of culture
with media exchanges every 2 days, the total amount of TGFβ
delivered in the soluble form is 55 ng/gel. In contrast, incorpo-
rating tethered TGFβ at 100 nM required 100 ng/gel, while the
10 nM gels used only 10-ng growth factor/gel to achieve a
similar level of chondrogenesis. Further, tethering growth fac-
tors or other proteins into an implantable biomaterial provides a
method tosignalcellsdelivered invivo, and thisapproachcould
Fig. 4 Glycosaminoglycan production by hMSCs encapsulated in
tethered TGFβ hydrogels. a ChSA production was quantified on a
per gel basis via the DMMB assay, and is a measure of cellular GAG
production, indicative of chondrogenesis. When TGFβ was tethered at
1 nM, GAG production was limited and similar in magnitude to that of
hydrogels cultured in growth medium, which acts as a negative control
condition for chondrogenesis. At higher concentrations (10 and
100 nM) of tethered TGFβ, GAG production exceeded that of the
positive control (chondrogenic media), where TGFβ was dosed solu-
bly. b–e Safranin-O staining shows GAG distribution in the pericellu-
lar space for chondrogenic media culture (c), as well at 10 (e) and
100 nM (f) tethered TGFβ gels. Gels culture in growth media (b) and
those with 1-nM tethered TGFβ (d) had negligible staining for GAGs.
Scale bar0100 μm
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be readily used to presentmultiple protein signals to cells, even
in various regions of a single material.
Histological analyses of MSC cultured in tethered TGFβ
hydrogels for extended time periods provide a spatial repre-
sentation of GAG deposition (Fig. 4b). Hydrogels were
harvested at day 21, cryosectioned, and stained with
Safranin-O, which stains GAGs red and counterstained with
haematoxylin with stains nuclei blue/black. Gels cultured in
growth medium had negligible red color surrounding nuclei,
confirming data obtained from the DMMB assay. Likewise,
gels incorporating 1-nM tethered TGFβ have a low level of
proteoglycan content, observed by faint staining. In contrast,
hydrogels cultured in chondrogenic media had significant
GAG deposition in the pericellular region and beyond, as
did gels formed with either 10- or 100-nM tethered TGFβ.
Since this hydrogel platform has no degradable crosslinks,
there is limited interstitial space for deposition of secreted
ECM and this leads to some of the observed spatial hetero-
geneity. However, this data agrees with previously pub-
lished work on GAG deposition for primary chondrocytes
encapsulated in similar PEG-based materials [35, 36].
Collagen II production in tethered TGFβ hydrogels
Collagen type II secretion is another hallmark of chondrogenic
differentiation of hMSCs, while expression of the CD-105 cell
surface marker is often used as one of the characteristic
markers for undifferentiated hMSC [22, 33, 37]. To further
characterize the role that tethered TGFβ plays in promoting
later stages of chondrogenesis, cell-laden gels were harvested
after 21 days of culture for immunostaining. Samples were
stained for type II collagen, CD-105, and DAPI to visualize
cell nuclei. Representative images are presented in Fig. 5.
Growth samples express the CD-105 marker to a greater
degree than any samples cultured in chondrogenic conditions
(green in Fig. 5), and only 2.2±0.6 % were positive for
collagen II. Interestingly, while 1-nM tethered TGFβ hydro-
gels did not produce appreciable amounts of GAGs (Fig. 4),
cells encapsulated in this gel formulation were negative for
CD-105 staining, while 5.5±0.7 % of cells counted were
positive for collagen II, suggesting that the MSCs may be
differentiating down other pathways. Cells encapsulated in
hydrogels formed with either 10-nM (84.0±13.9 %) or 100-
nM (91.0±0.2 %) tethered TGFβ were largely positive for
collagen II production (red in Fig. 5), similar to levels ob-
served with the positive control (89.3±7.2 %), chondrogenic
medium with soluble TGFβ.
Conclusions
Thiolated TGFβ was shown to maintain its bioactivity, and a
surface ELISA method was developed to confirm that TGFβ
was detectable following covalent incorporation in PEGDA
hydrogels. PE25 cells encapsulated in such tethered TGFβ
hydrogels were used to confirm that tethered TGFβ main-
tained its bioactivity when presented in this fashion. When
hMSCs were encapsulated in tethered TGFβ hydrogels, the
tethered growth factor promoted chondrogenic differentia-
tion at levels equal to or exceeding that of positive controls,
where TGFβ was dosed solubly via culture medium. Addi-
tionally, tethered TGFβ hydrogels utilized a lower total
dosage to promote differentiation. Collectively, these results
demonstrate the feasibility of delivering bioactive protein
signals in a 3D culture platform to control stem cell fate,
which may have further implications in the design of deliv-
ery vehicles for hMSCs to promote chondrogenesis and
cartilage regeneration in vivo.
Chondro
1 nM 10 nM
Growth
100 nM
Fig. 5 Immunostaining shows
collagen II (red) or CD-105
(green) production by hMSCs
encapsulated in PEG hydrogels.
Nuclei are counterstained with
DAPI (blue). Growth samples
were positive for CD-105, indi-
cating non-differentiated cells.
Gels cultured in chondrogenic
media with soluble TGFβ
expressed little CD-105, but
were positive for collagen II, a
hallmark of chondrogenic dif-
ferentiation. Cells cultured in
hydrogels with tethered TGFβ
at 1, 10, or 100 nM were all
positive for collagen II and
negative for CD-105. Scale
bar0200 μm
Drug Deliv. and Transl. Res. (2012) 2:305–312 311
Acknowledgments The authors would like to acknowledge Mark
Tibbitt and Abigail Bernard for assistance with confocal microscopy.
PE25 cells were a kind gift from Dr. Xuedong Liu. This work was
supported in part by grants from the NIH (R01 DE016523) and the
Howard Hughes Medical Institute.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
and reproduction in any medium, provided the original author(s) and
the source are credited.
References
1. Masters KS. Macromol Biosci. 2011;11(9):1149–63.
2. Tayalia P, Mooney DJ. Adv Mater. 2009;21(32–33):3269–85.
3. Lee SJ. Yonsei Med J. 2000;41(6):704–19.
4. Beck L, DAmore PA. FASEB J. 1997;11(5):365–73.
5. Eswarakumar VP, Lax I, Schlessinger J. Cytokine Growth F R.
2005;16(2):139–49.
6. Lutolf MP, Hubbell JA. Nat Biotechnol. 2005;23(1):47–55.
7. Tibbitt MW, Anseth KS. Biotechnol Bioeng. 2009;103(4):655–63.
8. Leslie-Barbick JE, Moon JJ, West JL. J Biomat Sci-Polym E.
2009;20(12):1763–79.
9. Saik JE, Gould DJ, Watkins EM, Dickinson ME, West JL. Acta
Biomater. 2011;7(1):133–43.
10. Li L; Klim JR; Derda R; Courtney AH; Kiessling LL, Proc Natl
Acad Sci U S A. 2011.
11. Mann BK, Schmedlen RH,West JL. Biomaterials. 2001;22(5):439–44.
12. Hume, P. S.; He, J.; Haskins, K.; Anseth, K. S., Biomaterials 2012;
33, (14), 3615–3625.
13. Kopesky PW, Vanderploeg EJ, Kisiday JD, Frisbie DD, Sandy JD,
Grodzinsky AJ. Tissue Eng Part A. 2011;17(1–2):83–92.
14. DeForest CA, Anseth KS. Angew Chem Int Ed. 2012;51(8):1816–9.
15. Aimetti AA, Machen AJ, Anseth KS. Biomaterials. 2009;30
(30):6048–54.
16. Nuttelman CR, Tripodi MC, Anseth K. Matrix Biol. 2005;24
(3):208–18.
17. Benton JA, Fairbanks BD, Anseth KS. Biomaterials. 2009;30
(34):6593–603.
18. Schwartz MP, Fairbanks BD, Rogers RE, Rangarajan R, Zaman
MH, Anseth KS. Integr Biol. 2010;2(1):32–40.
19. Bryant SJ, Nuttelman CR, Anseth KS. J Biomat Sci-Polym E.
2000;11(5):439–57.
20. Fairbanks BD, Schwartz MP, Bowman CN, Anseth KS.
Biomaterials. 2009;30(35):6702–7.
21. Lin CC, Sawicki SM, Metters AT. Biomacromolecules. 2008;9
(1):75–83.
22. Salinas CN, Anseth KS. Biomaterials. 2008;29(15):2370–7.
23. Kloxin AM, Kasko AM, Salinas CN, Anseth KS. Science.
2009;324(5923):59–63.
24. Lin CC, Boyer PD, Aimetti AA, Anseth KS. J Contr Release.
2010;142(3):384–91.
25. Lin CC, Anseth KS. Adv Funct Mater. 2009;19(14):2325–31.
26. Aimetti AA, Tibbitt MW, Anseth KS. Biomacromolecules.
2009;10(6):1484–9.
27. Salinas CN, Cole BB, Kasko AM, Anseth KS. Tissue Eng.
2007;13(5):1025–34.
28. Salinas CN, Anseth KS. Macromolecules. 2008;41(16):6019–26.
29. Lin CC, Anseth KS. Proc Natl Acad Sci U S A. 2011;108
(16):6380–5.
30. Clarke DC, Brown ML, Erickson RA, Shi YG, Liu XD. Mol Cell
Biol. 2009;29(9):2443–55.
31. Johnstone B, Hering TM, Caplan AI, Goldberg VM, Yoo JU. Exp
Cell Res. 1998;238(1):265–72.
32. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO,
Pittenger MF. Tissue Eng. 1998;4(4):415–28.
33. Sekiya I, Vuoristo JT, Larson BL, Prockop DJ. Proc Natl Acad Sci
U S A. 2002;99(7):4397–402.
34. Anderson SB, Lin CC, Kuntzler DV, Anseth KS. Biomaterials.
2011;32(14):3564–74.
35. Bryant SJ, Anseth KS. J Biomed Mater Res. 2002;59(1):63–
72.
36. Roberts JJ, Nicodemus GD, Giunta S, Bryant SJ. J Biomed Mater
Res Part A. 2011;97A(3):281–91.
37. Kim IL, Mauck RL, Burdick JA. Biomaterials. 2011;32
(34):8771–82.
312 Drug Deliv. and Transl. Res. (2012) 2:305–312
